Onkologie. 2021:15(2):73-76 | DOI: 10.36290/xon.2021.014

Hepatitis B and vaccination in relation to cancer

Petra Macounová, Rastislav Maďar
Ústav epidemiologie a ochrany veřejného zdraví, Lékařská fakulta, Ostravská univerzita, Ostrava

The hepatitis B virus is classified as carcinogenic to humans. Chronic hepatitis B infection is the most common etiological agent of hepatocellular carcinoma worldwide. There is evidence that the hepatitis B virus is also associated with other types of tumors, such as intrahepatic cholangiocarcinoma, pancreatic ductal adenocarcinoma, B-cell lymphoma, and others. However, there is effective prevention of hepatitis B in the form of vaccination. The vaccine against this infection was the first to be shown to be effective in preventing tumors and is considered a great success in the clinical chemoprevention of hepatocellular carcinoma, which is why it is part of national vaccination programs in children (who have the worst prognosis). Hepatitis B poses a risk to cancer patients treated with chemotherapy, so it is advisable to provide them HBV screening before treatment and, as a result, to protect patients from infection with either vaccines or antivirals.

Keywords: hepatitis B, vaccination, prevention, epidemiology, cancer.

Published: April 29, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Macounová P, Maďar R. Hepatitis B and vaccination in relation to cancer. Onkologie. 2021;15(2):73-76. doi: 10.36290/xon.2021.014.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Iarc monographs on the identification of carcinogenic hazards to humans: List of Classifications. International Agency for Research on Cancer: (IARC) [online]. [cit. 2021-01-13]. Dostupné z: https://monographs.iarc.fr/list-of-classifications.
    2. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. The Lancet Oncology [online]. 2009; 10(4): 321-322 [cit. 2021-01-13]. ISSN 14702045. Dostupné z: doi:10.1016/S1470-2045(09)70096-8. Go to original source... Go to PubMed...
    3. Tsai HJ. Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine. Taiwanese Journal of Obstetrics and Gynecology [online]. 2015; 54(2): 112-115 [cit. 2021-01-19]. ISSN 10284559. Dostupné z: doi:10.1016/j.tjog.2013.11.009. Go to original source... Go to PubMed...
    4. Beneš J. Infekční lékařství. Praha: Galén, 2009: 651 s.
    5. Burns G, Thompson A. Viral Hepatitis B: Clinical and Epidemiological Characteristics. Cold Spring Harbor Perspectives in Medicine [online]. 2014; 4(12): 024935-024935 [cit. 2021-01-13]. ISSN 2157-1422. Dostupné z: doi:10.1101/cshperspect.a024935. Go to original source... Go to PubMed...
    6. Nebbia G, Peppa D, Maini K. Hepatitis B infection: current concepts and future challenges. QJM [online]. 2012; 105(2): 109-113 [cit. 2021-01-13]. ISSN 1460-2725. Dostupné z: doi:10.1093/qjmed/hcr270. Go to original source... Go to PubMed...
    7. Hepatitis B Questions and Answers for Health Professionals. Centers for Disease Control and Prevention (CDC) [online]. [cit. 2021-01-13]. Dostupné z: https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#overview.
    8. Levreno M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. Journal of Hepatology [online]. 2016; 64(1): 84-101 [cit. 2021-01-13]. ISSN 01688278. Dostupné z: doi:10.1016/j.jhep.2016.02.021. Go to original source... Go to PubMed...
    9. Chaturvedi V, Singh A, Dubey S, et al. Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma. Microbial Pathogenesis [online]. 2019; 128: 184-194. [cit. 2021-01-13]. ISSN 08824010. Dostupné z: doi: 10.1016/j.micpath.2019.01.004. Go to original source... Go to PubMed...
    10. Chang MH. Cancer Prevention by Vaccination Against Hepatitis B. In: Senn HJ, Kapp U, Otto F, et al. Cancer Prevention II [online]. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009: s. 85-94 [cit. 2021-01-19]. Recent Results in Cancer Research. ISBN 978-3-540-69296-6. Dostupné z: doi:10.1007/978-3-540-69297-3_10. Go to original source...
    11. Macounová P. Virové hepatitidy v Pardubickém kraji. Ostrava, 2019. Diplomová práce. Ostravská univerzita, Lékařská fakulta. Vedoucí práce RNDr. Aleš Hozák.
    12. Novotvary ČR [online]. Praha: Ústav zdravotnických informací a statistiky České republiky (ÚZIS), 2016 [cit. 2021-01-18]. Dostupné z: https://www.uzis.cz/sites/default/files/knihovna/novotvary2016.pdf.
    13. Tomášek J, Tuček Š, Andrašina T. Hepatocelulární karcinom - diagnostika a terapie z pohledu klinického onkologa. Gastroenterologie a hepatologie. https://www.prolekare.cz/casopisy/ceska-slovenska-gastro/archiv-cisel/2011-3-5 \\o Gastroenterologie a hepatologie 3/2011 Gastroent Hepatol 2011; 65(3): 149-153 .
    14. Chang MH. Prevention of Hepatitis B Virus Infection and Liver Cancer. In: Wu TC, Chang MH, Jeang KT, et al. Viruses and Human Cancer [online]. Cham: Springer International Publishin, 2021: 71-90 [cit. 2021-01-20]. Recent Results in Cancer Research. ISBN 978-3-030-57361-4. Dostupné z: doi:10.1007/978-3-030-57362-1_4. Go to original source...
    15. Jeong S, Tong Y, Sha M, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncotarget 2016; 8: 10. Dostupné také z: https://www.oncotarget.com/article/14079/text/. Go to original source... Go to PubMed...
    16. Sinha M, Sundar K, Premalata CS, et al. Pro-oncogenic, intra host viral quasispecies in Diffuse large B cell lymphoma patients with occult Hepatitis B Virus infection. Scientific Reports [online]. 2019; 9(1) [cit. 2021-01-19]. ISSN 2045-2322. Dostupné z: doi:10.1038/s41598-019-51157-1. Go to original source... Go to PubMed...
    17. Dumitrascu T, Pineau P. Is Hepatitis B Virus a Player in Pancreatic Cancer? Chirurgia [online]. Bucharest 2018; 113(3): 344-352 [cit. 2021-01-19]. Dostupné z: doi:10.21614/chirurgia.113.3.344. Go to original source... Go to PubMed...
    18. Desai R, Patel U, Sharma S, et al. Association Between Hepatitis B Infection and Pancreatic Cancer: A Population-Based Analysis in the United States. Pancreas [online]. 2018; 47(7): 849-855 [cit. 2021-01-19]. ISSN 0885-3177. Dostupné z: doi:10.1097/MPA.0000000000001095. Go to original source... Go to PubMed...
    19. Liu X, Zhang Z, Jinag F. Hepatitis B virus infection increases the risk of pancreatic cancer: a meta-analysis. Scandinavian Journal of Gastroenterology [online]. 2021; 1-7 [cit. 2021-01-19]. ISSN 0036-5521. Dostupné z: doi:10.1080/00365521.2020.1868568. Go to original source... Go to PubMed...
    20. Tian T, Song C, Jiang L, et al. Hepatitis B virus infection and the risk of cancer among the Chinese population. International Journal of Cancer [online]. 2020; 147(11): 3075-3084 [cit. 2021-01-19]. ISSN 0020-7136. Dostupné z: doi:10.1002/ijc.33130. Go to original source... Go to PubMed...
    21. Song C, Lv J, Liu Y, et al. Associations Between Hepatitis B Virus Infection and Risk of All Cancer Types. JAMA Network Open [online]. 2019, 2(6) [cit. 2021-01-19]. ISSN 2574-3805. Dostupné z: doi:10.1001/jamanetworkopen.2019.5718. Go to original source... Go to PubMed...
    22. Hepatitis B: Key facts. World Health Organization [online]. [cit. 2021-01-19]. Dostupné z: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
    23. Chang MH, You SL, Chen ChJ, et al. Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. Gastroenterology [online]. 2016; 151(3): 472-4801 [cit. 2021-01-19]. ISSN 00165085. Dostupné z: doi:10.1053/j.gastro.2016.05.048. Go to original source... Go to PubMed...
    24. Qu Ch, Chen T, Fan Ch, et al. Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial. PLoS Medicine [online]. 2014; 11: (12) [cit. 2021-01-19]. ISSN 1549-1676. Dostupné z: doi:10.1371/journal.pmed.1001774 Go to original source... Go to PubMed...
    25. ČESKO. Vyhláška č. 537 ze dne 29. listopadu 2006 o očkování proti infekčním nemocem. In: Sbírka zákonů České republiky. 2006; 174: 7282-7287. Dostupný také z: https://www.psp.cz/sqw/sbirka.sqw?cz=537&r=2006.
    26. Bozza C, Cinausero M, Iacono D, et al. Hepatitis B and cancer: A practical guide for the oncologist. Critical Reviews in Oncology/Hematology [online]. 2016; 98: 137-146 [cit. 2021-01-20]. ISSN 10408428. Dostupné z: doi: 10.1016/j.critrevonc.2015.10.017. Go to original source... Go to PubMed...
    27. Leber K. Introduction of routine hepatitis B screening for all patients receiving cancer treatment. Neth J Med [online]. 2019; 77(1): 19-24 [cit. 2021-01-20]. Dostupné z: https://pubmed.ncbi.nlm.nih.gov/30774100/.
    28. The Lancet Gastroenterology & Hepatology. Undiagnosed hepatitis in patients with cancer. The Lancet Gastroenterology & Hepatology [online]. 2019; 4(4): 255 [cit. 2021-01-20]. ISSN 24681253. Dostupné z: doi: 10.1016/S2468-1253(19)30050-0. Go to original source... Go to PubMed...
    29. Husa P, Šperl J, Urbánek P et al. Diagnosis and therapy of hepatitis B virus infection - Czech national guidelines. Gastroenterologie a hepatologie [online]. 2017; 71(5): 419-437. [cit. 2021-01-20]. ISSN 18047874. Dostupné z: doi: 10.14735/amgh2017419. Go to original source...
    30. Altinoz MA, Ozpinar A, Zopinar A, et al. Could hepatitis B vaccine act as an adjuvant to lower risk and relapses of cancer? Clinical and Experimental Pharmacology and Physiology [online]. 2019; 46(8): 694-704. [cit. 2021-01-19]. ISSN 0305-1870. Dostupné z: doi: 10.1111/1440-1681.13096. Go to original source... Go to PubMed...
    31. Altinoz MA, Ozpinar A, Ozpinar A, et al. Hypothesis: Could Hepatitis B vaccine act as an immune adjuvant in glioblastoma? Clues to conduct further epidemiological analyses. International Immunopharmacology [online]. 2020; 81. [cit. 2021-01-20]. ISSN 15675769. Dostupné z: doi: 10.1016/j.intimp.2019.106038. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.